Log in with your email address username.


[Correspondence] Everolimus in ileum neuroendocrine tumours

James Yao (March 5, p 968) and colleagues1 reported that everolimus was associated with significantly prolonged progression-free survival in patients with advanced, progressive neuroendocrine tumours in the lung or gastrointestinal tract. I would like to congratulate the authors for this well-designed phase 3 study. However, I have two main concerns regarding the study’s interpretation, especially relating to ileum neuroendocrine tumours.